News ArchivesRead News
Austrian Biotech Firm's Parkinson's Vaccine
Wednesday July 30, 2014
The Local - An Austrian company has developed a potentially viable vaccine for early-stage Parkinson's disease. The treatment, which is designed to slow or even stop progression of the disease, has undergone a Phase I clinical trial, from which data was released on Thursday in New York.
The treatment is based on a candidate vaccine known as PD01A, which lowers levels of alpha-synuclein. This is a brain protein which is believed to play an important role in maintaining a supply of synaptic vesicles in presynaptic terminals, as well as helping to regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.
The trial was conducted at the Confraternität Privatklinik Josefstadt in Vienna and involved up to 32 patients.
The preliminary results of the trial showed that the vaccine was well tolerated and safe, that it induced an immune response, and that the immune response appeared to be improving function.
"If you add all this together, I think we have the first evidence that would tell us that these findings are compatible with what we look for with disease modification," Achim Schneeberger, MD, chief medical officer of AFFiRiS, the Austrian pharmaceutical company developing the drug, told a press conference where the initial results were released.
AFFiRiS AG employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria where the vaccine was developed. In addition to its work on the Parkinson's vaccine, the company has been developing peptide vaccines for Alzheimer's disease and Atherosclerosis.
In part, the research was funded by the Michael J. Fox Foundation to the tune of $1.5 million (€1.12 million). The foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. Its founder, Michael J. Fox, is a well-known Canadian-American actor who is a high-profile victim of the disease.
(30 July 2014). The Local. Austrian Biotech Firm's Parkinson's Vaccine. http://www.thelocal.at/20140730/austrian-biotech-to-release-parkinsons-vaccine-data
Recent NewsFeb 20 - February 20, 2018 News Update
Feb 13 - February 13, 2018 News Update
Feb 6 - February 6, 2018 News Update
Jan 30 - January 30, 2018 News Update
Jan 23 - January 23, 2018 News Update
Jan 16 - January 16, 2018 News Update
Jan 9 - January 9, 2018 News Update
Jan 2 - January 2, 2018 News Update
Dec 26 - December 26, 2017 News Update
Dec 19 - December 19, 2017 News Update
Dec 8 - New technique scours the genome for genes that combat disease
Dec 8 - Restless sleep may be an early sign of Parkinson's, dementia
Dec 1 - Defects in cell's 'waste disposal system' linked to Parkinson's
Dec 1 - Dual virtual reality/treadmill exercises promote brain plasticity in Parkinson's patients
Nov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him
Nov 17 - Focused ultrasound shows promise for treating Parkinson's tremor
Nov 17 - New research to target air pollution as a potential trigger for Parkinson’s
Nov 17 - This device will let you feel what it's like to suffer from Parkinson's
Nov 10 - How does Parkinson's disease influence depression?
Nov 10 - House votes to repeal ObamaCare's Medicare cost-cutting board